ZLDAF (Zelira Therapeutics) FFO per Share

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Zelira Therapeutics FFO per Share?

FFO per Share only applies to REITs.

Zelira Therapeutics Business Description

Address 101 St George’s Terrace, Level 3, Perth, WA, AUS, 6000
Zelira Therapeutics Ltd is an Australian biotechnology company that develops and commercializes cannabinoid-based medicines for a range of medical conditions. Its product portfolio includes proprietary formulations such as HOPE, Zenivol and Dalirex, targeting areas including insomnia, chronic pain, autism, eczema and other neurological and inflammatory conditions. The company advances these assets through clinical and preclinical research programs, and also sells medicinal cannabis products in Australia through prescription channels. Zelira operates across two geographic segments, Australia and the United States, where it has pursued partnerships and licensing arrangements to commercialize its formulations in the US market. Revenue is generated primarily from product sales of its medicinal cannabis formulations and from licensing and collaboration agreements with partners. The company is headquartered in Perth, Western Australia, and its shares are listed on the Australian Securities Exchange.